Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
DiaSorin and Cytek Biosciences have announced an agreement for Cytek to acquire substantially all assets of DiaSorin's Flow Cytometry & Imaging (FCI) business unit. This strategic transaction is expected to close within 30 days, enhancing Cytek's product offerings with advanced imaging and flow cytometry solutions. The FCI unit, which includes a network of over 7,000 installed instruments, will expand Cytek's global reach. This move aligns with DiaSorin's strategic focus on core business areas, as highlighted in their recent investor communications.
Cytek Biosciences (Nasdaq: CTKB) is set to report its financial results for Q4 and full year 2022 after market close on February 28, 2023. A conference call will follow at 1:30 PM PT to discuss results, business developments, and future outlook. Cytek is recognized for its Full Spectrum Profiling™ (FSP™) technology, enhancing cell analysis solutions through precision and sensitivity. Their products are for research use only in most markets, with some available for clinical use in approved regions. Investors should monitor Cytek's website and social media for updates and disclosures.
Cytek Biosciences (Nasdaq: CTKB) has announced a strategic partnership with Bio-Rad Laboratories to enhance its flow cytometry systems. This collaboration introduces Bio-Rad's StarBright™ Dyes, which are known for their superior brightness and stability. These dyes will be utilized to develop reagents that support high-parameter applications on Cytek's Aurora and Northern Lights™ systems. The partnership aims to improve multiparameter analysis capabilities, allowing researchers to design better panels. Cytek plans to optimize single vial reagents and multicolor panels for over 1,500 Full Spectrum Profiling™ instruments deployed worldwide.
Cytek Biosciences (Nasdaq: CTKB) announced its participation in upcoming investor conferences, starting with the 2023 BTIG MedTech Conference from February 14-16 in Snowbird, UT, where management will engage in one-on-one meetings with investors. Additionally, Cytek will be at the Cowen 43rd Annual Health Care Conference in Boston, MA, presenting a fireside chat and Q&A on March 8 at 12:50 p.m. ET. The company specializes in innovative cell analysis solutions powered by its patented Full Spectrum Profiling™ technology, which enhances precision in multiplexing analysis. More details are available on Cytek's website.
Cytek Biosciences (Nasdaq: CTKB) launched Cytek Cloud, a cloud-based platform aimed at enhancing flow cytometry workflows. This integrated solution consolidates spectral panel design tools, streamlining experiments pre-instrument use. It accelerates insights across various applications like immunology and oncology. Cytek's CEO, Dr. Wenbin Jiang, emphasized the commitment to redefining flow cytometry possibilities. Future enhancements for data management and analysis are planned. Cytek's technology enables high-resolution cellular analysis, enhancing researchers' capabilities in understanding biological systems.
Cytek Biosciences reported third quarter 2022 revenue of $40.5 million, an 18% year-over-year increase. Gross profit rose 26% to $26.9 million, achieving a gross profit margin of 66.4%. Net income improved to $1.6 million, with adjusted EBITDA reaching $7.3 million. The company expanded its installed base to 1,501 instruments, despite facing sales timing issues and currency headwinds. Cytek maintains its 2022 revenue outlook, estimating full-year figures between $160 million and $168 million.
Cytek Biosciences (Nasdaq: CTKB) has appointed Chris Williams as Chief Operating Officer to enhance operations and scalability. Williams aims to drive global operations, leveraging his experience from Thermo Fisher and Bayer Pharmaceuticals. His focus will be on cellular biology and supporting Cytek's growth in new markets. This strategic leadership change is positioned to optimize efficiency as Cytek targets larger markets. Williams holds a Mechanical Engineering degree from the University of Texas at Austin and brings extensive industry expertise.
Cytek Biosciences (Nasdaq: CTKB) announced it will release its financial results for Q3 2022 after market close on November 9, 2022. A conference call will take place at 1:30 PM PT / 4:30 PM ET to discuss the results and future outlook. Cytek is a leader in cell analysis solutions, noted for its Full Spectrum Profiling™ technology, which enhances multiplexing precision and sensitivity in cell analysis. Products include the Aurora and Northern Lights™ systems and related reagents. While certain products are available for clinical use in specific regions, others are solely for research purposes.
Cytek Biosciences (Nasdaq: CTKB) will participate in the 31st Annual Credit Suisse Healthcare Conference on November 9th, presenting at 3:50 PM PT / 6:50 PM ET. The presentation will be accessible via a live and archived webcast on the company’s website. Cytek specializes in cell analysis solutions through its innovative Full Spectrum Profiling™ technology, enhancing cell analysis precision and sensitivity. Products are primarily for research use, with some clinical use in approved regions. For more, visit cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) announced its participation in the 20th Annual Morgan Stanley Global Healthcare Conference on September 14, 2022, at 11:45 a.m. ET. A live webcast will be available on its website for interested parties. Cytek is a leader in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP™) technology for advanced cell analysis tools. Its product lineup includes the Aurora and Northern Lights systems and a comprehensive suite of reagents, software, and services.